Praxis Precision Medicines, Inc.
PRAX
Updated: 23/09/2026, 11:06:59
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
No summaries found.
- Share price
- $300.65
- Market cap
- $8.38B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Marcio Silva De'Souza
- Employees
- 168
- IPO date
- 16/10/2020
- Beta
- 2.778
- Last dividend
- $0.00
- Day range
- $298.40 – $312.46
- 52-week range
- $46.61 – $392.70
- 1-day performance
- 0.60%
- 1-year performance
- 545.03%
- Current drawdown (1Y)
- -23.44%
- CIK
- 0001689548
- CUSIP
- 74006W207
- ISIN
- US74006W2070
- Created
- 07/12/2025, 13:46:59
- Last update
- 23/09/2026, 11:06:59
Track Praxis Precision Medicines, Inc. with an AI analyst
See which prediction-market events move PRAX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Praxis Precision Medicines, Inc. (PRAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 08/06/2026, 18:38:31
Praxis' Premium Price May Reflect Unrealistic Market Prospects In Essential Tremor
Seeking Alpha • STOCK • 05/06/2026, 17:23:28
Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Target Lowered After Drug Study Setback
Market Data • Market Data • 02/06/2026, 15:17:21
Praxis Precision's epilepsy drug misses main goal of mid-to-late stage study
Reuters • STOCK • 01/06/2026, 20:11:32
Truist Financial Initiates Coverage on Praxis Precision Medicines (NASDAQ: PRAX) with Buy Rating
Market Data • Market Data • 13/05/2026, 17:10:58
Praxis Precision Medicines, Inc. (PRAX) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Seeking Alpha • STOCK • 12/05/2026, 23:30:51
Praxis Precision Medicines, Inc. (PRAX) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 09/05/2026, 15:21:17
Praxis Precision Medicines Q1 Earnings Call Highlights
MarketBeat • STOCK • 08/05/2026, 18:15:28
Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference
GlobeNewsWire • STOCK • 04/05/2026, 18:01:00
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
GlobeNewsWire • STOCK • 14/04/2026, 09:30:00
Praxis: Strong Buy As Relutrigine Submission Accepted Plus Expansion Potential
Seeking Alpha • STOCK • 06/04/2026, 18:10:15
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
GlobeNewsWire • STOCK • 30/03/2026, 18:01:00